FY23 Corporate Strategy and Sustainability Journey
Biologics - We are scaling-up to build a global Biosimilars business
in Horizon-1 and CGT and CDMO in Horizon-2
We are building a Global biosimilars business with Highly Regulated Market Approvals focused on
development of Monoclonal Antibodies and complex fusion proteins
Building
Biologics
Scaling-up current Biosimilars
business
# Out-licensed product
PEG-GCSF: Launched in US and Europe markets with our partner
•
Rituximab: Completed Global Safety Efficacy trials and expected filing for regulated markets by Q1 FY24
We have a current portfolio of 6 commercial products in India and in 27+ Emerging Markets
Robust pipeline of $50Bn+ of Innovator Peak Sales
Focus areas: Oncology & Auto-Immune disease
12
Products in pipeline
across various stages of
development; 1 approved
By
FY24
•
Other Modalities such as Anti-body Drug
Conjugates, Cell-Gene Therapy
5 products in clinical phase
2 additional products scaled-up
CDMO Biologics
20
© copyright Dr. Reddy's Ltd.View entire presentation